

NEVADA HEALTH AUTHORITY

Nevada Medicaid

4070 Silver Sage Drive Carson City, NV 89701 NVHA.NV.GOV



Silver State Scripts Board Meeting Minutes

Date of Meeting: Thursday, September 18, 2025, at 1:00 PM

Name of Organization: The State of Nevada, Nevada Health Authority, Nevada Medicaid, Silver State Scripts Board.

Agenda Item	Record		Notes
1. Closed Executive Session			
A. Call to Order and Roll Call	Chairperson Mark Decerbo called the meeti September 18, 2025. Chairperson Decerbo took the roll.	ng to order at 1:02 PM on	Nevada Medicaid Staff Present were as follows: • Duncan, Keiko, Pharm.D., Medicaid Pharmacy Director
	 Mark Decerbo, Pharm.D., Chair Joseph Adashek, MD Mark Crumby, Pharm. D. Elizabeth Gonzalez, Pharm.D. Sapandeep Khurana, MD Leana Ramirez, Pharm.D. Aditi Singh, MD 	Present Absent Absent D D D D D D D D D D D D D	 Brown, Antonio, Chief of Pharmacy & DMEPOS Palomino, Bonnie, Pharmacy Services Manager Flowers, Ellen, Social Services Program Specialist II Lither, Gabriel, Senior Deputy Attorney General (SDAG) Prime Staff Present were as
			follows: • Deoliveira, Brittany, Pharm.D., Clinical Account Manager

		 Czechowski, Jessica, Pharm.D., Director, Clinical Account Services Martinez, Chris, Sr. Business Analyst Rivas, Melissa, Sr. Business Analyst
B. Financial Review of Drug	Chairperson Decerbo directed Dr. Brittany Deoliveira to proceed with	
Classes with Proposed	the Financial Review of Drug classes with proposed changes up for	
Changes	review.	
	Dr. Deoliveira reminded the board members that the financial material presented is confidential and should not be discussed or disclosed outside this closed session of the Silver States Scripts Board meeting. Dr. Deoliveira presented the financial review of the established drug classes with proposed changes, noting the products with proposed changes in PDL status. • Anticonvulsants • Atypical Antipsychotics – Oral/Topical • Topical Antivirals • Bladder Antispasmodics • Rapid-Acting Insulins • Pre-Mixed Insulin Combinations • Bile Acid Sequestrants • Narcolepsy Agents • Ophthalmic Corticosteroids • Platelet Inhibitors • Anxiolytics, Sedatives, and Hypnotics • Gastrointestinal Anti-inflammatory Agents	
	Functional Gastrointestinal Disorder Drugs	
	Acne Agents: Topical, Benzoyl Peroxide, Antibiotics, and	
l.	Combination Products	

	Topical Retinoids		
	Dr. Deoliveira presented the financial reviewed for proposed addition:	ew of the new drug c	classes
	Functional Gastrointestinal Disorder D	rugs: Diarrhea-Predo	ominant
2. Open Public Meeting			
A. Call to Order and Roll Call	Chairperson Decerbo called the meeting to	o order at 2:05 PM or	
	September 18, 2025.		follows:
	A quorum was present.		 Duncan, Keiko, Pharm.D., Medicaid Pharmacy Director Brown, Antonio, Chief of
	Chairperson Decerbo took the roll.		Pharmacy & DMEPOS
	· ·	Present	Absent • Palomino, Bonnie, Pharmacy
	Mark Decerbo, Pharm.D., Chair		☐ Services Manager
	 Joseph Adashek, MD 		■ Flowers, Ellen, Social Services
	Mark Crumby, Pharm.D.		Program Specialist II
	Elizabeth Gonzalez, Pharm.D.		Lither, Gabriel, Senior Deputy
	Sapandeep Khurana, MD		Attorney General (SDAG)
	Leana Ramirez, Pharm.D.	_	☐ Prime Staff Present were as
	Aditi Singh, MD		follows:
	, Marti Singh, Wib	Ц	Deoliveira, Brittany, Pharm.D.,
			Clinical Account Manager
			 Czechowski, Jessica, Pharm.D., Director, Clinical Account Services
			Martinez, Chris, Sr. Business
			Analyst
			Rivas, Melissa, Sr. Business Applyst
			Analyst
			The public attendee list is included

					as Attachment A. Note: Participants may not have chosen to reveal their identity, and in the absence of a sign-in sheet, the attendee list's accuracy is not assured.
B. Approval for previous	Board Member Sapandeep Khurana mov			_	
Meeting Minutes from June 12, 2025.	minutes and Board Member Elizabeth Go	onzalez secor	ided the	motion.	
	A vote was taken, and the results were as				
	attendance (in favor, against, and abster	tions where	applicab	le):	
		Yes	No	Abst.	
	Mark Decerbo, Pharm.D., Chair	\boxtimes			
	 Joseph Adashek, MD 	\boxtimes			
	 Mark Crumby, Pharm.D. 	\boxtimes			
	 Elizabeth Gonzalez, Pharm.D. 	\boxtimes			
	 Sapandeep Khurana, MD 	\boxtimes			
	 Leana Ramirez, Pharm.D. 	\boxtimes			
	Aditi Singh, MD			\boxtimes	
C. Public Comments	Telephonic and web comments were call were opened. No Public comment was provided.	ed for, and t	he phon	e lines	
D. Status Update by NVHA	Chief of Pharmacy Services, Antonio Brow	wn, provided	an anno	uncement.	
	 First, as many of you know, we have o Nevada Health Authority under the Di- are no longer operating under DHCFP. our mission remains the same and the 	vision of Nev While the na	ada Med ame has	licaid. We changed,	

We remain committed to strengthening our work and continuing to improve the impact we make together.	
 Next, I'd like to just take a moment to recognize and say farewell to one of our valued board members, Dr. Ward. Dr. Ward began serving in 2017 with the Pharmacy and Therapeutics Committee, and has been with Silver State Scripts Board since its creation in 2019. Over the years, she has brought a wealth of clinical insight, thoughtful perspective and unwavering dedication to our work. Her contribution has been instrumental in shaping the direction and success of this board, and her presence will be deeply missed. On behalf of Nevada Medicaid and the many individuals and families we serve, we extend our heartfelt thanks to Dr. Ward. We wish her all the best in her future endeavors and hope she continues making meaningful impacts in whatever her path leads. Finally, as always, I'd like to remind everyone that we are actively recruiting practicing pharmacists and physicians to serve on our board. If you or someone you know may be interested, please do not hesitate to reach out to rxinfo@nvha.nv.org Thank you again for being here today and for continued commitment to the health and well-being of Nevada. 	
Telephonic and web comments were called for, and the phone lines were opened.	
Public comment was provided by Herbert Peoples, Medical Outcomes Liaison for UCB.	
	 Next, I'd like to just take a moment to recognize and say farewell to one of our valued board members, Dr. Ward. Dr. Ward began serving in 2017 with the Pharmacy and Therapeutics Committee, and has been with Silver State Scripts Board since its creation in 2019. Over the years, she has brought a wealth of clinical insight, thoughtful perspective and unwavering dedication to our work. Her contribution has been instrumental in shaping the direction and success of this board, and her presence will be deeply missed. On behalf of Nevada Medicaid and the many individuals and families we serve, we extend our heartfelt thanks to Dr. Ward. We wish her all the best in her future endeavors and hope she continues making meaningful impacts in whatever her path leads. Finally, as always, I'd like to remind everyone that we are actively recruiting practicing pharmacists and physicians to serve on our board. If you or someone you know may be interested, please do not hesitate to reach out to rxinfo@nvha.nv.org Thank you again for being here today and for continued commitment to the health and well-being of Nevada. Telephonic and web comments were called for, and the phone lines were opened. Public comment was provided by Herbert Peoples, Medical Outcomes

ii.	Drug class review presentation by Prime.	Dr. Deoliveira recommended the Board c therapeutically equivalent.	onsider the o	class clini	cally and		
iii.	Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	Board Member Joseph Adashek moved to and therapeutically equivalent as present Member Khurana seconded the motion. A vote was taken, and the results were as attendance (in favor, against, and absten	ed by Prime follows fron	, and Boa	ers in		
		 Mark Decerbo, Pharm.D., Chair Joseph Adashek, MD Mark Crumby, Pharm.D. Elizabeth Gonzalez, Pharm.D. Sapandeep Khurana, MD Leana Ramirez, Pharm.D. Aditi Singh, MD 	Yes X X X X X X	No	Abst.		
iv.	Presentation of recommendations for PDL inclusion by Prime.	 Dr. Deoliveira recommended: Keeping the carbamazepine products a and Carbatrol from preferred to non-pnon-preferred. Keeping the divalproex generic product branded Depakote products from prefered. Keeping the generic ethosuximide product brand Zarontin from preferred to reference to reference to reference to product as generic felbamate to non-preferred. Keeping lamotrigine tablets, dispersible tablets (ODT) and XR formulations as planictal brand tablets, dispersible tablets (ODT) to non-preferred. 	eferred, and erred to non- luct as prefe on-preferred preferred and e tablets, ora	d placing ed and m preferre rred and d. id movin	Equetro as coving the id. moving the grating the		

		 Moving lamotrigine dose pack and OD to preferred; and moving Lamictal dospreferred. Keeping Celontin as preferred, as place product as non-preferred. Placing the generic perampanel product Fycompa branded formulations to normal Removing the obsolete product Gabiting generic product tiagabine as non-preference. Removing Qudexy XR from the PDL dust Defining the preferred strengths of top and 25 mg, and non-preferring the top strength. And lastly, removing Depakene from the discontinuation. 	se packs from ing methsuxing act as preferred. ril from the PI erred. se to product piramate spring	preferred mide ger ed and m DL and p disconting nkle as t nkle 50 r	neric noving lacing its nuation. he 15 mg		
v	. Board Member Comments	Comment was provided by Board Memb	er Khurana.				
		Comment was provided by Board Memb	er Adashek.				
vi	 Discussion by Board and action by Board for approval of drugs for inclusion on the PDL. 	Board Member Adashek moved to appropriate presented by Prime and Board Member motion.					
		A vote was taken, and the results were as					
		attendance (in favor, against, and abster	ntions where a	applicab	le):		
			Yes	No	Abst.		
		Mark Decerbo, Pharm.D., Chair	\boxtimes				
		 Joseph Adashek, MD 	\boxtimes				
		Mark Crumby, Pharm.D.	\boxtimes				
		Elizabeth Gonzalez, Pharm.D.	\boxtimes				
		Sapandeep Khurana, MD	\boxtimes				

		 Leana Ramirez, Pharm.D. 	\boxtimes			
		Aditi Singh, MD			\boxtimes	
R Fo	or Possible Action: Discussion					
	nd possible adoption of					
	typical Antipsychotics –					
Oı	ral/Topical.					
i.	Public comment	Telephonic and web comments were c	alled for, and th	ne phon	e lines	
		were opened.	, , , , , ,	- 1		
					_	
		Public comment was provided by Aarol Bristol-Myers Squibb.	n Fayes, HUR Fi	eld Scie	ntist at	
		Bristor-wiyers squibb.				
		Public comment was provided by Amy	Hale, Pharmaci	st and P	rincipal	
		Scientific Account Lead with Johnson &	k Johnson Innov	ative M	edicine.	
ii.	Drug class review	Dr. Deoliveira discussed Cobenfy. She p	nresented the a	vailahili	ty within	
""	presentation by Prime.	the drug class and noted the indication				
		efficacy studies.				
		Do Doolii isiaa waxaa aa dad dha Baasa		مالم مالم	:!!	
		Dr. Deoliveira recommended the Board therapeutically equivalent.	a consider the d	iass ciin	ically and	
		the appearagn equivalent				
iii.	Discussion by Board and	Board Member Adashek moved to acce	•		•	
	action by Board to	therapeutically equivalent as presented	d by Prime and	Chairpe	rson	
	approve clinical/therapeutic	Decerbo seconded the motion.				
	equivalency of agents in	A vote was taken, and the results were	as follows from	n memb	ers in	
	class.	attendance (in favor, against, and abst				
		AAA Baar ta Bhaar B. Cl	Yes	No	Abst.	
		 Mark Decerbo, Pharm.D., Chair 	\boxtimes			

		 Joseph Adashek, MD 	\boxtimes		
		Mark Crumby, Pharm.D.	\boxtimes		
		Elizabeth Gonzalez, Pharm.D.	\boxtimes		
		Sapandeep Khurana, MD	\boxtimes		
		• Leana Ramirez, Pharm.D.	\boxtimes		
		Aditi Singh, MD			\boxtimes
iv.	Presentation of	Dr. Deoliveira recommended:			
	recommendations for PDL	Moving Saphris from preferred to non-	preferred, a	nd inste	ad
	inclusion by Prime.	preferring the generic asenapine			
		 Moving Fanapt from preferred to non- 	preferred		
		Placing Cobenfy as non-preferred			
		 Removing Fazaclo from the PDL due to 	product disc	continua	tion
	D 114 1 0 1		1/1		
V.	Board Member Comments	Comment was provided by Board Member	er Khurana.		
		Comment was provided by Board Membe	er Adashek		
		Comment was provided by Board Weinbo	er Addstick.		
		Comment was provided by Board Membe	er Gonzalez.		
		,			
vi.	Discussion by Board and	Chairperson Decerbo moved to approve		_	
	action by Board for	presented by Prime with the exception of	f placing Cob	enfy as	preferred
	approval of drugs for	instead of non-preferred, and Board Mer	nber Adashe	k second	led the
	inclusion on the PDL.	motion.			
			Yes	No	Abst.
		Mark Decerbo, Pharm.D., Chair		\boxtimes	
		 Joseph Adashek, MD 	\boxtimes		
		Mark Crumby, Pharm.D.	\boxtimes		
		Elizabeth Gonzalez, Pharm.D.	\boxtimes		
		Sapandeep Khurana, MD	\boxtimes		
		 Leana Ramirez, Pharm.D. 	\boxtimes		
		Aditi Singh, MD			\boxtimes

ar	or Possible Action: Discussion and possible adoption of opical Antivirals.						
i.	Public Comment	Telephonic and web comments were call were opened.	ed for, and th	ne phone	lines		
		No public comment was provided.					
ii.	Drug class review presentation by Prime.	Dr. Deoliveira recommended the Board of therapeutically equivalent.	onsider the c	lass clini	cally and		
iii.	Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	Board Member Adashek moved to accept herapeutically equivalent as presented I Gonzalez seconded the motion. A vote was taken, and the results were as attendance (in favor, against, and abster	oy Prime and s follows from	Board M	lember ers in		
			Yes	No	Abst.		
		Mark Decerbo, Pharm.D., Chair	\boxtimes				
		 Joseph Adashek, MD 	X				
		Mark Crumby, Pharm.D.	\boxtimes				
		 Elizabeth Gonzalez, Pharm.D. 	\boxtimes				
		 Sapandeep Khurana, MD 	\boxtimes				
		 Leana Ramirez, Pharm.D. 	\boxtimes				
		Aditi Singh, MD			\boxtimes		
iv.	Presentation of recommendations for PDL inclusion by Prime.	 Dr. Deoliveira recommended: Two drugs in this class (Xerese cream are no longer participating in the MDR will be removed from the PDL Prime recommends no further change 	P as of 10/1/		· ·		

V.	Discussion by Board and action by Board for approval of drugs for	Board Member Adashek moved to appropresented by Prime and Chairperson Dec	erbo secondo	ed the m	otion.	
	inclusion on the PDL.	A vote was taken, and the results were as attendance (in favor, against, and absten				
			Yes	No	Abst.	
		Mark Decerbo, Pharm.D., Chair	\boxtimes			
		Joseph Adashek, MD	\boxtimes			
		Mark Crumby, Pharm.D.	\boxtimes			
		Elizabeth Gonzalez, Pharm.D.	\boxtimes			
		Sapandeep Khurana, MD	\boxtimes			
		Leana Ramirez, Pharm.D.	\boxtimes			
		Aditi Singh, MD			\boxtimes	
an	or Possible Action: Discussion and possible adoption of ladder Antispasmodics.					
i.	Public Comment	Telephonic and web comments were call were opened.	ed for, and th	ne phone	e lines	
		Public comment was provided by Jeff Ne. America in the Medical Affairs Group.	sheim from S	umitom	o Pharma	
ii.	Drug class review presentation by Prime.	Dr. Deoliveira recommended the Board of the the source of	onsider the c	lass clini	cally and	
iii.	Discussion by Board and	Board Member Adashek moved to accep				
	action by Board to approve clinical/therapeutic	therapeutically equivalent as presented becerbo seconded the motion.	by Prime and	Chairpe	rson	
	equivalency of agents in class.	A vote was taken, and the results were as attendance (in favor, against, and absten				

			Yes	No	Abst.
		Mark Decerbo, Pharm.D., Chair	\boxtimes		
		 Joseph Adashek, MD 	\boxtimes		
		Mark Crumby, Pharm.D.	\boxtimes		
		Elizabeth Gonzalez, Pharm.D.	\boxtimes		
		Sapandeep Khurana, MD	\boxtimes		
		Leana Ramirez, Pharm.D.	\boxtimes		
		Aditi Singh, MD			\boxtimes
iv.	Presentation of	Dr. Deoliveira recommended:			
	recommendations for PDL	Keeping Detrol and Detrol LA preferre			
	inclusion by Prime.	been confirmed to be discontinued), a	_	_	
		tolterodine (both the IR and ER formu	lations) from	non-pre	ferred to
		preferredMoving the brand Toviaz from preferr	ed to non-nre	forred	and placing
		the generic product fesoterodine ER a	•	ileireu,	and placing
		Keeping the oxybutynin IR 5 mg tablet	•	and det	fining the
		oxybutynin IR 2.5 mg tablet as non-pro	•		
		Moving the brand Myrbetriq ER tablet		referred	to
		preferred, keeping the Myrbetriq grar			l, and
		placing the generic mirabegron ER tab	-		
		And lastly, removing the discontinued	products: Dit	ropan X	L,
	Discussion by Doord and	Gelnique, and Sanctura.	wa tha nrana	sad abs	2222
V.	Discussion by Board and action by Board for	Board Member Adashek moved to appropries presented by Prime and Board Member			
	approval of drugs for	presented by Filme and board Welliber	Miluialia SECO	nucu III	c modon.
	inclusion on the PDL.	A vote was taken, and the results were a			
		attendance (in favor, against, and abster	ntions where a	applicab	le):
			.,		
		Add Book to Bloom B. Cl.	Yes	No	Abst.
		Mark Decerbo, Pharm.D., Chair	\boxtimes		
		 Joseph Adashek, MD 	\boxtimes		

		Mark Crumby, Pharm.D.	\boxtimes			
		Elizabeth Gonzalez, Pharm.D.	\boxtimes			
		Sapandeep Khurana, MD	\boxtimes			
		Leana Ramirez, Pharm.D.	\boxtimes			
		Aditi Singh, MD			⊠	
an	or Possible Action: Discussion and possible adoption of apid-Acting Insulins.			-	-	
i.	Public Comment	Telephonic and web comments were cal were opened.	led for, and t	ne phon	e lines	
		No public comment was provided.				
ii.	Drug class review presentation by Prime.	Dr. Deoliveira recommended the Board of therapeutically equivalent.	consider the o	lass clin	ically and	
iii.	Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	Board Member Adashek moved to accept therapeutically equivalent as presented Decerbo seconded the motion. A vote was taken, and the results were attendance (in favor, against, and abster	by Prime and s follows fron	Chairpe	rson ers in	
			Yes	No	Abst.	
		Mark Decerbo, Pharm.D., Chair	\boxtimes			
		Joseph Adashek, MD	\boxtimes			
		Mark Crumby, Pharm.D.	\boxtimes			
		Elizabeth Gonzalez, Pharm.D.	\boxtimes			
		Sapandeep Khurana, MD	\boxtimes			
		• Leana Ramirez, Pharm.D.	_ ⊠			
		Aditi Singh, MD	П	П	\square	

iv. Presentation of recommendations for PDL inclusion by Prime.	Dr. Deoliveira recommended: • Moving brand Novolog from non-prefe	erred to prefe	erred		
v. Board Member Comments	Comment was provided by Board Memb	er Khurana.			
vi. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	Board Member Adashek moved to appropriate presented by Prime and Chairperson Dec A vote was taken, and the results were a attendance (in favor, against, and abster	cerbo secondo s follows from	ed the m	otion. ers in	
		Yes	No	Abst.	
	Mark Decerbo, Pharm.D., Chair	X			
	Joseph Adashek, MD	X			
	Mark Crumby, Pharm.D.	X			
	Elizabeth Gonzalez, Pharm.D.	X			
	Sapandeep Khurana, MD	\boxtimes			
	Leana Ramirez, Pharm.D.	\boxtimes			
	Aditi Singh, MD			\boxtimes	
F. For Possible Action: Discussion and possible adoption of Pre-Mixed Insulin Combinations.					
i. Public Comment	Telephonic and web comments were cal were opened.	led for, and th	ne phone	lines	
	No public comment was provided.				
ii. Drug class review	Dr. Deoliveira recommended the Board of	consider the c	lass clini	cally and	
presentation by Prime.	therapeutically equivalent.				

iii.	Discussion by Board and	Chairperson Decerbo moved to accept th					
action by Board to		therapeutically equivalent presented by Prime and Board Member					
	approve	Gonzalez seconded the motion.					
	clinical/therapeutic						
	equivalency of agents in	A vote was taken, and the results were as					
	class.	attendance (in favor, against, and absten	tions where	applicab	le):		
			Yes	No	Abst.		
		Mark Decerbo, Pharm.D., Chair	\boxtimes				
		 Joseph Adashek, MD 	\boxtimes				
		Mark Crumby, Pharm.D.	\boxtimes				
		• Elizabeth Gonzalez, Pharm.D.	\boxtimes				
		Sapandeep Khurana, MD	\boxtimes				
		• Leana Ramirez, Pharm.D.	\boxtimes				
		Aditi Singh, MD			\boxtimes		
iv.	Presentation of	Dr. Deoliveira recommended:					
	recommendations for PDL	Moving brand Novolin 70/30 and Novo					
	inclusion by Prime.	to preferred.	-				
٧.	Discussion by Board and	Board Member Adashek moved to appro	ve the propo	sed cha	nges as		
	action by Board for	presented by Prime and Board Member (Gonzalez seco	onded th	ne motion.		
	approval of drugs for				_		
	inclusion on the PDL.	A vote was taken, and the results were as					
		attendance (in favor, against, and absten	tions where a	аррисар	ie):		
			Yes	No	Abst.		
		Mark Decerbo, Pharm.D., Chair	\boxtimes				
		 Joseph Adashek, MD 	\boxtimes				
		Mark Crumby, Pharm.D.	\boxtimes				
		Elizabeth Gonzalez, Pharm.D.	\boxtimes				
		Sapandeep Khurana, MD	\boxtimes				

		Leana Ramirez, Pharm.D.	\boxtimes				
		Aditi Singh, MD			\boxtimes		
	or Possible Action: Discussion						
	nd possible adoption of Bile						
A	cid Sequestrants.						
i.	Public Comment	Telephonic and web comments were ca were opened.	lled for, and tl	ne phon	e lines		
		No public comment was provided.					
ii.	Drug class review presentation by Prime.	Dr. Deoliveira recommended the Board therapeutically equivalent.	consider the c	class clin	ically and		
iii.	Discussion by Board and	Board Member Adashek moved to acce	nt the class as	clinicall	y and	+	
111.	action by Board to	therapeutically equivalent as presented	•		•		
	approve clinical/therapeutic	Decerbo seconded the motion.	ay rriiire aria	onan pe	.50		
	equivalency of agents in	A vote was taken, and the results were a	as follows from	n membe	ers in		
	class.	attendance (in favor, against, and abste					
			V.	N 1 -	Alexa		
		Mark Decerbo, Pharm.D., Chair	Yes ⊠	No □	Abst. □		
		Joseph Adashek, MD	⊠				
		Mark Crumby, Pharm.D.					
		Elizabeth Gonzalez, Pharm.D.	⊠				
		Sapandeep Khurana, MD	⊠				
		Leana Ramirez, Pharm.D.	⊠				
		Aditi Singh, MD					
iv.	Presentation of	Dr. Deoliveira recommended:	Ц				
IV.	recommendations for PDL	Moving brand Welchol from preferred	d to non profe	errod an	d instand		
	inclusion by Prime.	VIOVING DIGITAL WEIGHOUT FOR PRESENTE	u to non-preis	iieu all	u iiistedu		

		preferring the generic colesevalem.					
V.	Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	Board Member Adashek moved to approx presented by Prime and Board Member G A vote was taken, and the results were as attendance (in favor, against, and abstent	Sonzalez seco	nded th	e motion.		
			Yes	No	Abst.		
		Mark Decerbo, Pharm.D., Chair	\boxtimes				
		 Joseph Adashek, MD 	\boxtimes				
		 Mark Crumby, Pharm.D. 	\boxtimes				
		 Elizabeth Gonzalez, Pharm.D. 	\boxtimes				
		 Sapandeep Khurana, MD 	\boxtimes				
		 Leana Ramirez, Pharm.D. 	X				
		 Aditi Singh, MD 			\boxtimes		
an	r Possible Action: Discussion d possible adoption of arcolepsy Agents.						
i.	Public Comment	Telephonic and web comments were calle were opened.	ed for, and th	e phone	e lines		
		No public comment was provided.					
ii.	Drug class review presentation by Prime	Dr. Deoliveira recommended the Board co therapeutically equivalent.	onsider the c	lass clini	cally and		
iii.	Discussion by Board and	Board Member Adashek moved to accept					
	action by Board to approve clinical/therapeutic	therapeutically equivalent as presented b Decerbo seconded the motion.	y Prime and	Chairpei	rson		
	equivalency of agents in	A vote was taken, and the results were as	follows from	membe	ers in		
	class.	attendance (in favor, against, and abstent	tions where a	pplicabl	e):		
			Yes	No	Abst.		
		 Mark Decerbo, Pharm.D., Chair 	\boxtimes				

ľ			 Joseph Adashek, MD 	\boxtimes				
			 Mark Crumby, Pharm.D. 	\boxtimes				
			 Elizabeth Gonzalez, Pharm.D. 	\boxtimes				
			 Sapandeep Khurana, MD 	\boxtimes				
			 Leana Ramirez, Pharm.D. 	\boxtimes				
			Aditi Singh, MD			\boxtimes		
Ī	iv. Pre	esentation of	Dr. Deoliveira recommended:					
		recommendations for PDL inclusion by Prime.	Moving Nuvigil from preferred to non-preferred and instead					
	inc		preferring the generic armodafinil.					
			And placing the generic for Xyrem (sodium oxybate solution) as non-					
			preferred.					
		scussion by Board and tion by Board for	Board Member Adashek moved to appropriate presented by Prime and Board Member			_		
		proval of drugs for						
	inc	lusion on the PDL.	A vote was taken, and the results were as follows from members in					
			attendance (in favor, against, and abster	ntions where	applicab	le):		
				.,		•1 .		
			Mad Basada Blassa B. Claria	Yes	No	Abst.		
			Mark Decerbo, Pharm.D., Chair					
			Joseph Adashek, MD					
			Mark Crumby, Pharm.D.	\boxtimes				
			Elizabeth Gonzalez, Pharm.D.	\boxtimes				
			 Sapandeep Khurana, MD 	\boxtimes				
			 Leana Ramirez, Pharm.D. 	\boxtimes				
L			Aditi Singh, MD			\boxtimes		
		ssible Action: Discussion						
	•	ssible adoption of						
ļ		almic Corticosteroids.						
	i. Pul	blic Comment	Telephonic and web comments were cal	led for, and th	ne phon	e lines		
			were opened.					
			No public comment was provided.					
1			i No public collinelli was provided.					

ii. Drug class revie		pard consider the	class clin	ically and				
presentation by			المونوناور					
iii. Discussion by Baction by Board		pard Member Adashek moved to accept the class as clinically and perapeutically equivalent as presented by Prime and Board Member						
арргоуе	Gonzalaz seconded the motion.	inted by Prime and	i buaiu iv	hember				
clinical/therape								
equivalency of a		ere as follows fror	n membe	ers in				
class.	attendance (in favor, against, and a							
		Yes	No	Abst.				
	 Mark Decerbo, Pharm.D., Chair 	\boxtimes						
	 Joseph Adashek, MD 	\boxtimes						
	 Mark Crumby, Pharm.D. 	\boxtimes						
	 Elizabeth Gonzalez, Pharm.D. 	\boxtimes						
	 Sapandeep Khurana, MD 	\boxtimes						
	 Leana Ramirez, Pharm.D. 	\boxtimes						
	 Aditi Singh, MD 			\boxtimes				
iv. Presentation of	Dr. Deoliveira recommended:							
recommendation inclusion by Prince	moving the predmodicine gener	ic product from n	on-prefe	rred to				
	Removing Omnipred from the P	DI as this produc	st has ha	on				
	discontinued.	DL, as this produc	L Has be	en				
v. Discussion by B		annroya tha nrong	acad char	200 20				
v. Discussion by B action by Board approval of dru	d for presented by Prime and Board Men							
inclusion on the		ere as follows fror	n membe	ers in				
	attendance (in favor, against, and a							
				•				
		Yes	No	Abst.				
	Mark Decerbo, Pharm.D., Chair	\boxtimes						
	 Joseph Adashek, MD 	\boxtimes						
	Mark Crumby, Pharm.D.	\boxtimes						

		Elizabeth Gonzalez, Pharm.D.	X				
		Sapandeep Khurana, MD	\boxtimes				
		Leana Ramirez, Pharm.D.	\boxtimes				
		Aditi Singh, MD			\boxtimes		
а	or Possible Action: Discussion nd possible adoption of latelet Inhibitors.						
i.	Public Comment	Telephonic and web comments were call	led for, and t	he phone	e lines		
		were opened.		•			
		No public comment was provided.					
ii.	Drug class review	Dr. Deoliveira recommended the Board consider the class clinically and					
	presentation by Prime	therapeutically equivalent.					
iii.	Discussion by Board and	Board Member Adashek moved to accept the class as clinically and					
	action by Board to	therapeutically equivalent as presented I	by Prime and	Board m	nember		
	approve clinical/therapeutic	Gonzalez seconded the motion.					
	equivalency of agents in	A vote was taken, and the results were as follows from members in					
	class.	attendance (in favor, against, and absten	itions where	applicab	le):		
			Yes	No	Abst.		
		Mark Decerbo, Pharm.D., Chair	\boxtimes				
		 Joseph Adashek, MD 	\boxtimes				
		Mark Crumby, Pharm.D.	\boxtimes				
		Elizabeth Gonzalez, Pharm.D.	\boxtimes				
		Sapandeep Khurana, MD	\boxtimes				
		Leana Ramirez, Pharm.D.	\boxtimes				
		Aditi Singh, MD			\boxtimes		
		j ,	_	_			

iv. Presentation of recommendations for PDL inclusion by Prime. v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	 Dr. Deoliveira recommended: Durlaza will be removed from the PDL participating in the MDRP Removing brand Aggrenox from the P discontinued and moving its generic (a preferred to preferred. Placing ticagrelor (the generic for Brili Board Member Adashek moved to appropresented by Prime and Board Member A vote was taken, and the results were a attendance (in favor, against, and abster 	DL, as this pro aspirin/dipyric nta) as non-pr ove the propos Gonzalez seco	duct has amole) eferred sed char inded th	s been from non- nges as e motion.	
	 Mark Decerbo, Pharm.D., Chair Joseph Adashek, MD Mark Crumby, Pharm.D. Elizabeth Gonzalez, Pharm.D. Sapandeep Khurana, MD Leana Ramirez, Pharm.D. Aditi Singh, MD 	Yes X X X X X X X	No	Abst.	
 K. For Possible Action: Discussion and possible adoption of Anxiolytics, Sedatives, and Hypnotics. i. Public Comment 	Telephonic and web comments were cal were opened.	led for, and th	e phone	e lines	
ii. Drug class review presentation by Prime.	No public comment was provided. Dr. Deoliveira recommended the Board therapeutically equivalent.	consider the c	lass clini	cally and	

iii.	Discussion by Board and	Chairperson Decerbo moved to accept th	e class as clir	nically a	nd			
	action by Board to	therapeutically equivalent as presented by	y Prime and	Board N	⁄lember			
	approve	Adashek seconded the motion.						
	clinical/therapeutic							
	equivalency of agents in	A vote was taken, and the results were as follows from members in						
	class.	attendance (in favor, against, and abstentions where applicable):						
			Yes	No	Abst.			
		Mark Decerbo, Pharm.D., Chair						
		Joseph Adashek, MD	\boxtimes					
		Mark Crumby, Pharm.D.						
		Elizabeth Gonzalez, Pharm.D.						
		Sapandeep Khurana, MD						
		Leana Ramirez, Pharm.D.						
					⋈			
		Aditi Singh, MD	Ш	Ш				
iv.	Presentation of	Dr. Deoliveira recommended:						
	recommendations for PDL	Moving brand Rozerem from preferred	to non-pref	erred, a	nd placing			
	inclusion by Prime.	its generic ramelteon as preferred						
		Keeping temazepam 7.5 mg, 15 mg, an	d 30 mg stre	ngths as	preferred,			
		and non-preferring the temazepam 22	.5 mg strengt	th				
		Moving sublingual zolpidem from prefer	erred to non-	preferre	ed			
		Defining the zolpidem capsule product	as non-prefe	erred				
		Moving zolpidem CR from non-preferre	ed to preferr	ed				
		Moving flurazepam from preferred to it.	non-preferre	d				
		Moving eszopiclone (the generic for Lu	nesta) from i	non-pre	ferred to			
		preferred	•	·				
		Removing Sonata and Zolpimist from the second	he PDL, as th	ese prod	ducts have			
		been discontinued						

v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	Board Member Adashek moved to approve presented by Prime and Board Member Gor A vote was taken, and the results were as for attendance (in favor, against, and abstention	zalez seco lows from	nded th	e motion.	
	 Mark Decerbo, Pharm.D., Chair Joseph Adashek, MD Mark Crumby, Pharm.D. Elizabeth Gonzalez, Pharm.D. Sapandeep Khurana, MD Leana Ramirez, Pharm.D. Aditi Singh, MD 	Yes X X X X X X X	No	Abst.	
L. For Possible Action: Discussion and possible adoption of Gastrointestinal Anti-Inflammatory Agents. i. Public Comment	Talanhania and wah sammants ware called	for and th	o nhone	linos	
i. Public Comment	Telephonic and web comments were called were opened. No public comment was provided.	or, and th	e pnone	ines	
ii. Drug class review presentation by Prime	Dr. Deoliveira recommended the Board constherapeutically equivalent.	ider the cl	ass clini	cally and	
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	Chairperson Decerbo moved to accept the continuous therapeutically equivalent as presented by Foundament and the motion. A vote was taken, and the results were as foliattendance (in favor, against, and abstention)	rime and I	Board M	lember ers in	
		Yes	No	Abst.	

		Mark Decerbo, Pharm.D., Chair	\boxtimes					
		 Joseph Adashek, MD 	\boxtimes					
		Mark Crumby, Pharm.D.	\boxtimes					
		Elizabeth Gonzalez, Pharm.D.	\boxtimes					
		Sapandeep Khurana, MD	\boxtimes					
		• Leana Ramirez, Pharm.D.	\boxtimes					
		Aditi Singh, MD			\boxtimes			
iv.	Presentation of	Dr. Deoliveira recommends:						
	recommendations for PDL inclusion by Prime.	 Apriso and Colazal will be removed fro participating in the MDRP 		-	_			
		 Moving mesalamine (the generic for Appreferred 	priso) from n	on-prefe	erred to			
		Moving mesalamine (the generic for Lialda) from non-preferred to preferred						
		Moving Pentasa from preferred to non-preferred, and defining its generic mesalamine product as non-preferred as well						
		Removing Delzicol from the PDL, as this product has been discontinued						
		Moving brand Canasa suppository from preferred to non-preferred, and instead preferring mesalamine suppository (the generic for Canasa)						
V.	Discussion by Board and action by Board for approval of drugs for	Board Member Adashek moved to appropresented by Prime and Chairperson Dec						
	inclusion on the PDL.	A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):						
			Yes	No	Abst.			
		Mark Decerbo, Pharm.D., Chair	\boxtimes					
		 Joseph Adashek, MD 	\boxtimes					
		Mark Crumby, Pharm.D.	\boxtimes					
		Elizabeth Gonzalez, Pharm.D.	\boxtimes					

		Sapandeep Khurana, MD	X			
		Leana Ramirez, Pharm.D.	\boxtimes			
		Aditi Singh, MD			\boxtimes	
M. For	r Possible Action: Discussion					
and	d possible adoption of					
	nctional Gastrointestinal					
	sorder Drugs.					
i.	Public Comment	Telephonic and web comments were cal were opened.	lled for, and t	ne phon	e lines	
		No public comment was provided.				
ii.	Drug class review presentation by Prime	Dr. Deoliveira recommended the Board therapeutically equivalent.	consider the o	class clin	ically and	
iii.	Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	Board Member Adashek moved to accept the class as clinically and therapeutically equivalent as presented by Prime and Chairperson Decerbo seconded the motion. A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):				
			Yes	No	Abst.	
		Mark Decerbo, Pharm.D., Chair	×			
		Joseph Adashek, MD	\boxtimes			
		Mark Crumby, Pharm.D.	\boxtimes			
		Elizabeth Gonzalez, Pharm.D.	\boxtimes			
		Sapandeep Khurana, MD	\boxtimes			
		Leana Ramirez, Pharm.D.	_ ⊠			
		Aditi Singh, MD			\boxtimes	
iv.	Presentation of	Dr. Deoliveira recommends:				
	recommendations for PDL	Relistor, Trulance, and Zelnorm will be	e removed fro	m the P	DL as they	
inclusion by Prime.		are no longer participating in the MDRP.				

v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	 Adding "constipation-related" to this class name on the PDL to differentiate it from the diarrhea-predominant drugs. Placing prucalopride (the generic for Motegrity) as non-preferred. Chairperson Decerbo moved to approve the proposed changes as presented by Prime and Board Member Adashek seconded the motion. A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable): 					
	 Mark Decerbo, Pharm.D., Chair Joseph Adashek, MD Mark Crumby, Pharm.D. Elizabeth Gonzalez, Pharm.D. Sapandeep Khurana, MD Leana Ramirez, Pharm.D. Aditi Singh, MD 	Yes X X X X X X X	No	Abst.		
N. For Possible Action: Discussion and possible adoption of Acne Agents: Topical, Benzoyl Peroxide, Antibiotics, and Combination Products.						
i. Public Comment	Telephonic and web comments were call were opened. No public comment was provided.	ed for, and th	ne phone	e lines		
ii. Drug class review presentation by Prime	Dr. Deoliveira recommended the Board consider the class clinically and therapeutically equivalent.					
iii. Discussion by Board and action by Board to approve	Board Member Adashek moved to accept the class as clinically and therapeutically equivalent as presented by Prime and Board Member Gonzalez seconded the motion.					

	clinical/therapeutic equivalency of agents in class.	A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):					
			Yes	No	Abst.		
		Mark Decerbo, Pharm.D., Chair	\boxtimes				
		 Joseph Adashek, MD 	\boxtimes				
		Mark Crumby, Pharm.D.	\boxtimes				
		Elizabeth Gonzalez, Pharm.D.	\boxtimes				
		Sapandeep Khurana, MD	\boxtimes				
		• Leana Ramirez, Pharm.D.	\boxtimes				
		Aditi Singh, MD			\boxtimes		
iv.	Presentation of recommendations for PDL inclusion by Prime.	 Dr. Deoliveira recommends: Acanya, Azelex, Amzeeq, and Onexton as they are no longer participating in the Placing clindamycin/benzoyl peroxide preferred, keeping all other clindamyc formulations as non-preferred. Removing Duac CS from the non-prefer has been discontinued. 	he MDRP. (the generic t in/benzoyl pe rred drug list	or Duac eroxide g , as this) as gel product		
V.	Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	Board Member Adashek moved to appropriate presented by Prime and Board Member (A vote was taken, and the results were as attendance (in favor, against, and absten	Gonzalez seco	onded th	ers in		
			Yes	No	Abst.		
		Mark Decerbo, Pharm.D., Chair	\boxtimes				
		 Joseph Adashek, MD 	X				
		Mark Crumby, Pharm.D.	\boxtimes				
		 Elizabeth Gonzalez, Pharm.D. 	\boxtimes				

		 Sapandeep Khurana, MD 	\boxtimes				
		 Leana Ramirez, Pharm.D. 	\boxtimes				
		Aditi Singh, MD			\boxtimes		
O. Fo	or Possible Action:						
Di	scussion and possible						
	doption of Topical						
	etinoids.						
i.	Public Comment	Telephonic and web comments were cal	lled for, and t	he phon	e lines		
		were opened.					
		No could:					
	Davis alasa assissu	No public comment was provided.		مانام مانام	امورو براامون		
ii.	Drug class review presentation by Prime	Dr. Deoliveira recommended the Board therapeutically equivalent.	consider the o	ciass ciin	ilcally and		
iii.	Discussion by Board and	Board Member Adashek moved to accept	nt the class as	clinicall	v and		
	action by Board to	therapeutically equivalent as presented			•		
	approve	Decerbo seconded the motion.	by i fillie and	Chanpe	.15011		
	clinical/therapeutic						
	equivalency of agents in	A vote was taken, and the results were as follows from members in					
	class.	attendance (in favor, against, and abstentions where applicable):					
			Yes	No	Abst.		
		 Mark Decerbo, Pharm.D., Chair 	\boxtimes				
		 Joseph Adashek, MD 	\boxtimes				
		 Mark Crumby, Pharm.D. 	\boxtimes				
		 Elizabeth Gonzalez, Pharm.D. 	\boxtimes				
		 Sapandeep Khurana, MD 	\boxtimes				
		• Leana Ramirez, Pharm.D.	\boxtimes				
		Aditi Singh, MD			\boxtimes		

iv.	Presentation of	Dr. Deoliveira recommends:					
	recommendations for PDL	Retin-A, Ziana, and Arazlo will be removed from the PDL as they are					
	inclusion by Prime.	no longer participating in the MDRP.					
		 Placing tretinoin cream as a preferred 	agent.				
		 Placing tretinoin gel (the generic for A 	vita and Retir	n-A) as p	referred		
		and placing tretinoin gel (the generic f	or Atralin) as	non-pre	ferred.		
		Defining the tretinoin microspheres get	•	-			
		change, just clarifying due to some tre	tinoin produc	cts shifti	ng		
		positions in this class).					
		Placing clindamycin/tretinoin combina	•				
		Placing Twyneo (the brand only combination product of tretinoin and					
		benzoyl peroxide) as non-preferred.					
		Removing Avita from the PDL, as this part of the PDL.	oroduct has b	een disc	ontinuea.		
V.	Discussion by Board and	Board Member Adashek moved to approve the proposed changes as					
	action by Board for	presented by Prime and Board Member Gonzalez seconded the motion.					
	approval of drugs for inclusion on the PDL. A vote was taken, and the results were as follows from members in						
	inclusion on the PDL.	A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):					
		attenuance (iii lavor, against, and abster	itions where a	аррпсав	ie).		
			Yes	No	Abst.		
		 Mark Decerbo, Pharm.D., Chair 	\boxtimes				
		 Joseph Adashek, MD 	\boxtimes				
		 Mark Crumby, Pharm.D. 	\boxtimes				
		 Elizabeth Gonzalez, Pharm.D. 	X				
		 Sapandeep Khurana, MD 	\boxtimes				
		Leana Ramirez, Pharm.D.	\boxtimes				
		Aditi Singh, MD			\boxtimes		
	ew Drug Class Being						
	eviewed for Proposed						
	ddition: Functional						
G	astrointestinal Disorder						

	ugs: Diarrhea- edominant.					
i.	Public Comment	Telephonic and web comments were call were opened.	ed for, and th	he phone	e lines	
		No public comment was provided.				
ii.	Drug class review presentation by Prime	Dr. Deoliveira discussed Lotronex, Viberz availability within the drug class and not action, and efficacy studies.				
		Dr. Deoliveira recommended the Board of therapeutically equivalent.				
iii.	Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	Board Member Adashek moved to accept the class as clinically and therapeutically equivalent as presented by Prime and Board Member Gonzalez seconded the motion. A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):				
			Yes	No	Abst.	
		Mark Decerbo, Pharm.D., Chair	\boxtimes			
		 Joseph Adashek, MD 	\boxtimes			
		Mark Crumby, Pharm.D.	\boxtimes			
		• Elizabeth Gonzalez, Pharm.D.	\boxtimes			
		Sapandeep Khurana, MD	\boxtimes			
		Leana Ramirez, Pharm.D.	\boxtimes			
		Aditi Singh, MD			\boxtimes	
iv.	Presentation of recommendations for PDL inclusion by Prime	 Dr. Deoliveira recommends: Lotronex and Viberzi be placed as pref Alosetron (the generic for Lotronex) be 		on-prefe	rred.	

1								
V.	Discussion by Board and	Board Member Adashek moved to approve the proposed changes as presented by Prime and Board Member Gonzalez seconded the motion.						
	action by Board for approval of drugs for	presented by Prime and Board Member						
	inclusion on the PDL.	A vote was taken, and the results were a	s follows from	membe	ers in			
	merasion on the 1 BE.	attendance (in favor, against, and abster						
		, , , , ,		•	,			
			Yes	No	Abst.			
		 Mark Decerbo, Pharm.D., Chair 	\boxtimes					
		 Joseph Adashek, MD 	\boxtimes					
		 Mark Crumby, Pharm.D. 	\boxtimes					
		 Elizabeth Gonzalez, Pharm.D. 	\boxtimes					
		 Sapandeep Khurana, MD 	\boxtimes					
		 Leana Ramirez, Pharm.D. 	\boxtimes					
		Aditi Singh, MD			\boxtimes			
,	nnual Review: Established	• Analgesics: Miscellaneous Analgesics,	Neuropathic	Pain/Fib	romyalgia			
	rug Classes without	Agents, Mixed Acting Opioid Analgesic						
Pr	oposed Changes.	Agonists – Abuse Deterrents; Non-Opi	_	s; Non-S	teroidal			
		Anti-Inflammatory Drugs (NSAIDs) – O						
		Anti-Infective Agents: Aminoglyseside	_	sinoglyc	ocidos			
			 Anti-Infective Agents: Aminoglycosides, Inhaled Aminoglycosides; Antivirals, Alpha Interferons, Anti-hepatitis Agents – Polymerase 					
		Inhibitors/Combination Products, Anti	_					
		Anti-herpetic Agents, COVID-19, Influe			· ·			
		Second-Generation Cephalosporins, T						
		Macrolides; Quinolones, Quinolones -	- 2 nd generatio	n, Quin	olones – 3 rd			
		Generation; Topical Anti-Infectives, Va	_					
		Autonomic Agents: Sympathomimetic						
		Epinephrine						
		Biologic Response Modifiers: Immunomodulators, Immunomodulators: Atopic Dermatitis, Targeted Immunomodulator,						
		Colony Stimulating Factors, Immune G						
		Agents, Injectable, Oral, Specific Symp						
		genies, injectable, oral, opecine symp	tomatic fred					

- Cardiovascular Agents: Antihypertensive Agents, Angiotensin II
 Receptor Antagonists, Angiotensin-Converting Enzyme Inhibitors (ACE
 Inhibitors), Beta-Blockers, Calcium-Channel Blockers, Vasodilators –
 Inhaled, Vasodilators Oral; Antilipemics, Cholesterol Absorption
 Inhibitors, Fibric Acid Derivatives, HMG-CoA Reductase Inhibitors
 (Statins), Niacin Agents, Omega-3 Fatty Acids, PCSK9 Inhibitors;
 Miscellaneous Heart Failure Agents
- Dermatological Agents: Antipsoriatic Agents; Topical Analgesics; Topical Anti-infectives, Impetigo Agents: Topical, Topical Scabicides; Topical Antineoplastics; Topical Steroids, Steroids Topical Low, Steroids Topical Medium, Steroids Topical High, Steroids Topical Very High
- Electrolytes and Renal Agents: Phosphate Binding Agents; Potassium-Removing Agents
- Gastrointestinal Agents: Antiemetics, Pregnancy-induced Nausea and Vomiting Treatment, Serotonin-receptor Antagonists/Combo; Antiulcer Agents, H2 Blockers, Proton Pump Inhibitors (PPIs); Gastrointestinal Enzymes
- **Genitourinary Agents**: Benign Prostatic Hyperplasia (BPH) Agents, 5-Alpha Reductase Inhibitors, Alpha-Blockers
- **Hematological Agents**: Anticoagulants, Oral, Injectable; Erythropoiesis-Stimulating Agents
- Hormones and Hormone Modifiers: Androgens; Antidiabetic Agents, Alpha-Glucosidase Inhibitors/Amylin Analogs/Miscellaneous, Biguanides, Dipeptidyl Peptidase-4 Inhibitors and Combinations with Metformin, Incretin Mimetics and Combinations, Meglitinides, Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors and Combinations, Sulfonylureas, Thiazolidinediones and Combinations; Anti-Hypoglycemic Agents; Insulins, Short-Intermediate Acting Insulins, Long-Acting Insulins; Pituitary Hormones, Growth Hormone Modifiers; Progestins for Cachexia; Uterine Disorder Treatment
- Monoclonal Antibodies for the Treatment of Respiratory Conditions

i. Public Comment	 Musculoskeletal Agents: Antigout Agents; Bone Resorption Inhibitors, Bisphosphonates, Nasal Calcitonins; Restless Leg Syndrome Agents; Skeletal Muscle Relaxants Neurological Agents: Alzheimer's Agents, Cholinesterase Inhibitors, NMDA Receptor Antagonist, Barbiturates; Anticonvulsants, Benzodiazepines, Hydantoins; Anti-Migraine Agents, Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonists, Serotonin-Receptor Agonists (Triptans); Antiparkinsonian Agents, Dopamine Precursors, Non-Ergot Dopamine Agonists; Movement Disorders Ophthalmic Agents: Antiglaucoma Agents; Ophthalmic Macrolides, Ophthalmic Quinolones; Ophthalmic Anti-infective/Anti-inflammatory Combinations; Ophthalmic Anti-inflammatory agents, Ophthalmic Nonsteroidal Anti-inflammatory Drugs (NSAIDs); Ophthalmics for Dry Eye Disease Otic Agents: Otic Anti-infectives, Otic Quinolones Psychotropic Agents: ADHD Agents; Antidepressants, Other, Selective Serotonin Reuptake Inhibitors (SSRIs); Antipsychotics, Atypical Antipsychotics – Long Acting Injectable; Psychostimulants Respiratory Agents: Nasal Antihistamines; Respiratory Anti-Inflammatory Agents, Leukotriene Receptor Antagonists; Nasal Corticosteroids; Phosphodiesterase Type 4 Inhibitors or Combination; Long-Acting Maintenance Therapy, Inhaled Glucocorticoids, Glucocorticoids/Long-Acting Beta-2 Adrenergic (LABA) Combination Products, Long-Acting Beta Adrenergics (LABAs), Anticholinergics and Combination Products; Short-Acting Beta Adrenergics (SABAs), Ipratropium and Combinations Toxicology Agents: Antidotes, Opiate Antagonists; Substance Abuse Agents Appendix A: Sickle Cell Disease; HIV Prevention 	
i. Fublic Comment	were opened.	

	Public comment was provided by Brett Stevenson, Senior Director of Health Economics and Outcomes Research employed by
	Arcutis Biotherapeutics.
	Public comment was provided by Kyle Knudsen, Health Outcomes
	Liaison at Axon Therapeutics.
	B. His constant and the Bod and the Andrew Block to and
	Public comment was provided by Doctor John Andrews, Physician and Field Medical Director with Pfizer.
	Public comment was provided by Chris Dube, PharmD within Medical Affairs.
	Public comment was provided by Rich Oliver, MD, MSL Medical Science Liaison with Liquidia Corporation.
R. Prime Reports	New Drugs to Market and New Line Extensions
	Overview of notable FDA decisions expected for third quarter 2025
	Reviewed a new endocrine drug in the drug pipeline: relacorilant
	Reviewed a new renal drug in the drug pipeline: sibeprenlimab
	Reviewed a new neurology drug in the pipeline: tolebrutinib
4. Closing Discussion	
A. Public comments on any subject	No public comments were provided.
B. Date and location of the next	Date: December 11, 2025
meeting.	Location: Courtyard by Marriott Las Vegas Convention Center
	3275 Paradise Road, Las Vegas, NV, 89109
C. Adjournment	Chairperson Decerbo adjourned the meeting at 3:55 PM.

Attachment A – Members of the Public in Attendance

Aaron Feyos	Garrick Wong	Kent Douglas
Abraham Meza	Hiten Patadia	Krystal Ngo
Alisa Cadenhead	Jeana Colabianchi	Kyle Knudsen
Alletha Muzorewa	Jeff Nesheim	Lea Cartwright
Amy Hale	Jeffrey Nesheim	Lee Stout
Ann Marie O'Toole	Jenna Doerr	Lisa Glick
Brad Burris	Jesie MacDonald	Lisa Pulver
Brad Harrison	Jill Carroll	Lislie Costalin
Brett Stephenson	JJ Roth	Marc Parker
Cade Grogan	John Andrews	Maria Reyes
Christina Cobeo	John F	Melbye Rick
Christine Dube	Juli	Michael Faithe
David Gross	Julie Barbiere	Nora Francis
Dawn Fleming	Justin Clark	Pam Storey
Fushimi Brent	Justin May	Peeples Herbert

Reince Rittman
Rianna White
Richard Junk
Richard Oliver
Ryan A Roa
Ryan K Bitton
Shannon Sturtevant
Shawn Akey
Shelly Nickerson
Stefanie Abraham
Thomas L Beranek
Todd Dickerson
Tracy L Yarbrough

Attachment B – Submitted Written Comment

None